CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer
Drug Resistance Updates · 2023-03 · 67 · 100912
DOI: 10.1016/j.drup.2022.100912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2023-03. Verfasst von Ning Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Prostate cancer (PCa) is one of the most lethal causes of cancer-related death in male. It is characterized by chromosomal instability and disturbed signaling transduction. E3 ubiquitin ligases are well-recognized as mediators leading to genomic alterations and malignant phenotypes. There is a lack of systematic study on novel oncodrivers with genomic and clinical significance in PCa. In this study we used clustered regularly interspaced short palindromic repeats (CRISPR) system to screen 656 E3 ubiquitin ligases as oncodrivers or tumor repressors in PCa cells. We identified 51 significantly changed genes, and conducted genomic and clinical analysis on these genes. It was found that the Ring Finger Protein 19 A (RNF19A) was a novel oncodriver in PCa. RNF19A was frequently amplified and highly expressed in PCa and other cancer types. Clinically, higher RNF19A expression correlated with advanced Gleason Score and predicted castration resistance. Mechanistically, transcriptomics, quantitative and ubiquitination proteomic analysis showed that RNF19A ubiquitylated Thyroid Hormone Receptor Interactor 13 (TRIP13) and was transcriptionally activated by androgen receptor (AR) and Hypoxia Inducible Factor 1 Subunit Alpha (HIF1A). This study uncovers the genomic and clinical significance of a oncodriver RNF19A in PCa. The results of this study indicate that targeting AR/HIF1A-RNF19A-TRIP13 signaling axis could be an alternative option for PCa diagnosis and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Division of Urology, Department of Surgery, Queen Mary Hospital, Hong Kong, China; Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Division of Urology, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: yungna@hku.hk.
Zitieren
APA
Zhang, N., Huang, D., Ruan, X., Ng, A. T., Tsu, J. H., Jiang, G., Huang, J., Zhan, Y., & Na, R. (2023). CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer. Drug Resistance Updates, 67, 100912. https://doi.org/10.1016/j.drup.2022.100912
Vancouver
Zhang N, Huang D, Ruan X, Ng AT, Tsu JH, Jiang G, et al. CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer. Drug Resistance Updates. 2023;67:100912. doi:10.1016/j.drup.2022.100912
BibTeX
@article{Zhang2023,
author = {Zhang, Ning and Huang, Da and Ruan, Xiaohao and Ng, Ada Tsui-Lin and Tsu, James Hok-Leung and Jiang, Guangliang and Huang, Jingyi and Zhan, Yongle and Na, Rong},
title = {CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer},
journal = {Drug Resistance Updates},
year = {2023},
volume = {67},
pages = {100912},
doi = {10.1016/j.drup.2022.100912}
}
EUVIMED